These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 24757302)

  • 41. Effect of aripiprazole as an adjunct to atypical antipsychotics on weight and metabolic profile: a 12-week open-label trial.
    Gupta B; Chee KS; Neo LQ; Tang C; Hariram J; Tan GC; Verma S; Basu S; Appan DP; Ting CC; Abdin E; Lee J
    Ther Adv Psychopharmacol; 2021; 11():20451253211046765. PubMed ID: 34646440
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychoses.
    Melkersson KI; Hulting AL; Brismar KE
    J Clin Psychiatry; 1999 Nov; 60(11):783-91. PubMed ID: 10584769
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [The stabilizing effect of dehydroepiandrosterone on clinical parameters of metabolic syndrome in patients with schizophrenia treated with olanzapine - a randomized, double-blind trial].
    Holka-Pokorska JA; Radzio R; Jarema M; Wichniak A
    Psychiatr Pol; 2015; 49(2):363-76. PubMed ID: 26093599
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Previous exposure to antipsychotic drug treatment is an effective predictor of metabolic disturbances experienced with current antipsychotic drug treatments.
    Yang Y; Xie P; Long Y; Huang J; Xiao J; Zhao J; Yue W; Wu R
    BMC Psychiatry; 2022 Mar; 22(1):210. PubMed ID: 35313842
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
    Atmaca M; Kuloglu M; Tezcan E; Ustundag B
    J Clin Psychiatry; 2003 May; 64(5):598-604. PubMed ID: 12755665
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis.
    De Hert M; Yu W; Detraux J; Sweers K; van Winkel R; Correll CU
    CNS Drugs; 2012 Sep; 26(9):733-59. PubMed ID: 22900950
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A cross-sectional evaluation of adiponectin plasma levels in patients with schizophrenia and schizoaffective disorder.
    Hanssens L; van Winkel R; Wampers M; Van Eyck D; Scheen A; Reginster JY; Collette J; Peuskens J; De Hert M
    Schizophr Res; 2008 Dec; 106(2-3):308-14. PubMed ID: 18930377
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
    Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
    J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The impact of weight gain associated with atypical antipsychotic use in schizophrenia.
    Chue P; Cheung R
    Acta Neuropsychiatr; 2004 Jun; 16(3):113-23. PubMed ID: 26984162
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.
    Baptista T; Serrano A; Uzcátegui E; ElFakih Y; Rangel N; Carrizo E; Fernández V; Connell L; de Baptista EA; Quiroz S; Uzcátegui M; Rondón J; Matos Y; Uzcátegui L; Gómez R; Valery L; Novoa-Montero D
    Schizophr Res; 2011 Mar; 126(1-3):93-102. PubMed ID: 21071179
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Adjunctive effects of aripiprazole on metabolic profiles: comparison of patients treated with olanzapine to patients treated with other atypical antipsychotic drugs.
    Wang LJ; Ree SC; Huang YS; Hsiao CC; Chen CK
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():260-6. PubMed ID: 23085073
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
    L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
    J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study.
    Sikich L; Frazier JA; McClellan J; Findling RL; Vitiello B; Ritz L; Ambler D; Puglia M; Maloney AE; Michael E; De Jong S; Slifka K; Noyes N; Hlastala S; Pierson L; McNamara NK; Delporto-Bedoya D; Anderson R; Hamer RM; Lieberman JA
    Am J Psychiatry; 2008 Nov; 165(11):1420-31. PubMed ID: 18794207
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improvements in body composition, anthropometric measurements and lipid profile following discontinuation of clozapine.
    Wysokiński A; Sobów T
    Nord J Psychiatry; 2016; 70(2):156-60. PubMed ID: 26140393
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between levels of insulin or triglycerides and serum concentrations of the atypical antipsychotics clozapine and olanzapine in patients on treatment with therapeutic doses.
    Melkersson KI; Dahl ML
    Psychopharmacology (Berl); 2003 Nov; 170(2):157-66. PubMed ID: 12851739
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of Early Risperidone Treatment on Metabolic Parameters in Socially Isolated Rats-Implication of Antipsychotic Intervention across Developmental Stages of Schizophrenia.
    Tzeng NS; Yang YY; Lin CC; Hsieh PS; Liu YP
    J Integr Neurosci; 2023 Jan; 22(1):12. PubMed ID: 36722248
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Diabetic ketoacidosis associated with antipsychotic drugs: case reports and a review of literature.
    Vuk A; Kuzman MR; Baretic M; Osvatic MM
    Psychiatr Danub; 2017 Jun; 29(2):121-135. PubMed ID: 28636569
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metabolic side effects in persons with schizophrenia during mid- to long-term treatment with antipsychotics: a network meta-analysis of randomized controlled trials.
    Burschinski A; Schneider-Thoma J; Chiocchia V; Schestag K; Wang D; Siafis S; Bighelli I; Wu H; Hansen WP; Priller J; Davis JM; Salanti G; Leucht S
    World Psychiatry; 2023 Feb; 22(1):116-128. PubMed ID: 36640396
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The prevalence of metabolic syndrome in schizophrenic patients using antipsychotics.
    Ko YK; Soh MA; Kang SH; Lee JI
    Clin Psychopharmacol Neurosci; 2013 Aug; 11(2):80-8. PubMed ID: 24023552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients.
    Smith RC; Lindenmayer JP; Bark N; Warner-Cohen J; Vaidhyanathaswamy S; Khandat A
    Int J Neuropsychopharmacol; 2005 Jun; 8(2):183-94. PubMed ID: 15737248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.